Arrowhead Pharm had its Relative Strength (RS) Rating upgraded from 70 to 78 Wednesday — a welcome improvement, but still shy of the 80 or better score you look for.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily measures share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains typically have an 80 or better RS Rating in the early stages of their moves. See if Arrowhead Pharm can continue to rebound and hit that benchmark.
Arrowhead Pharm is not currently showing a potential entry point. See if the stock goes on to build a promising consolidation that could kick off a new price move.
Arrowhead Pharm reported 0% earnings growth last quarter, while sales growth came in at -30%.
The company holds the No. 195 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Anbio Biotechnology and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
